Feasibility of Day 4 G-CSF Mobilized Peripheral Blood Stem Collection from HLA-Matched Sibling Donors  by Newell, Laura F. et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S301431
Feasibility of Day 4 G-CSF Mobilized Peripheral Blood
Stem Collection from HLA-Matched Sibling Donors
Laura F. Newell 1, Rebekah J. Knight 2, Kelsea M. Shoop 3,
Sara N. Murray 2, Susan Slater 3, Richard T. Maziarz 4,
Gabrielle Meyers 5. 1 Center for Hematologic Malignancies,
Knight Cancer Institute, Oregon Health & Science University,
Portland, OR; 2 Center for Hematologic Malignancies, Oregon
Health and Science University, Portland, OR; 3 Center for
Hematologic Malignancies, Oregon Health & Science
University, Portland, OR; 4 Center for Hematologic
Malignancies, Knight Cancer Institute, Oregon Health and
Science University, Portland, OR; 5 Oregon Health & Science
University, Portland, OR
Background: Guidelines from the NMDP and ASBMT
recommend allogeneic donor mobilization with 4-5 days of
G-CSF followed by peripheral blood stem cell (PBSC) collec-
tion beginning the 5th day. While our institutional standard
has been 5-day mobilization and collection, given observa-
tions that some autologous transplant patients are
adequately mobilized by day 4, and due to concern that a
subset of allogeneic donors may be maximally mobilized
earlier than day 5, we performed a feasibility study evalu-
ating day 4 collection of allogeneic PBSC.
Methods: Beginning 7/1/2013, HLA-matched sibling donors
were collected on day 4 after G-CSF if the peripheral blood
(PB) CD34 count was 0.04x106/ml. Collected PBSC were
held overnight at 4⁰C until transplant. Donors with day 4 PB
CD34 counts of 0.04x106/ml were collected on day 5, and
those with inadequate CD34 cells/kg recipient weight in the
PBSC product underwent repeat collection over two days.
Results: 38 patients with matched-sibling donors were
eligible for inclusion in the study, with a median follow-up of
217 days (range 45-458). Of 38 donors evaluated, 22 (57.9%)
had a PB CD34 count 0.04x106/ml on day 4. Eighteen of the
22 (81.8%) were adequately collected on day 4; 3 required 2-
day PBSC collections on days 4 and 5. One donor with an
adequate PB CD34 count was collected on day 5 due to line
issues. Of the 16 donors with a PB CD34 count <0.04x106/ml,
7 underwent single day collection on day 5, and 9 required
two-day collections. Of all donors eligible for inclusion, 18
(47.4%) were adequately collected on day 4, 8 (21.1%) were
collected on day 5, and 31.6% required two-day collections.
There was no signiﬁcant difference in the median time to
ANC and platelet engraftment based on day of PBSC
collection.
Conclusions: In our pilot study of HLA-matched sibling do-
nors undergoing G-CSF mobilized PBSC collection, we found
that 47.4% of donors were adequatelymobilized to allow for a
single PBSC collection on day 4. Using a PB CD34 cell
threshold of 0.04x106/ml on day 4 identiﬁed donors withMedian Day 4 n¼18 Day 5 n¼8 Two-Days
n¼12
Donor/Recipient age (years) 51/51 51.5/51 56/58
Donor/Recipient weight (kg) 87.1/86.5 75.5/79.0 83.5/94.5
Day 4 PB CD343106/mL 0.07 0.028 0.024
PB CD343l06/mL at collection n/a 0.057 0.038
PBSC CD343l06/kg 7.43 5.38 2.72
TNC3108/kg 6.99 8.24 12.0
MNC3108/kg 5.84 7.51 10.7
CD33l08/kg 2.17 2.52 3.92
Day ANC >500/ml 13 14 15
Day platelets >203l09/L 17.5 17.5 18high likelihood of adequate PBSC collection (81.8%). Our
preliminary data suggest day 4 may be the optimal day of
collection for a population of healthy donors, reducing donor
G-CSF exposure leading to enhanced safety for donor and
recipient, and expected cost savings. Ongoing analyses
include ﬁnancial and resource utilization review, detailed
comparison of day 4 versus 5 PBSC product composition, and
matched cohort analysis of day 4 versus 5 collection and
correlation with transplant outcomes.432
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Background: Placental growth factor (PlGF) is a member of
the vascular endothelial growth factor (VEGF) family, with a
role in inﬂammation and monocyte chemotaxis. Pathologi-
cally high levels of PlGF have been described in the setting of
inﬂammatory diseases, and upregulation of the PlGF receptor
(VEGFR1) can be induced by vascular injury and inﬂamma-
tion. In a pilot study, we identiﬁed that circulating levels of
PlGF are signiﬁcantly elevated in recipients of allogeneic HCT.
Thus, we hypothesized that PlGF may play an immuno-
modulatory role post-HCT, and sought to quantify differ-
ences in circulating PlGF levels between HCT donors and
recipients, characterize peripheral blood mononuclear cell
(PBMC) expression of VEGFR1, and determine GVHD target
organ expression of PlGF.
Patients and Methods: Plasma and PBMCs from a cohort of
14 adult patients undergoing allogeneic HCT were collected
at 3 months post-HCT and compared to samples obtained
from their matched sibling donors (MSD). Plasma PlGF levels
were quantiﬁed by ELISA; PBMC expression of VEGFR1 was
determined by ﬂow cytometry. Immunohistochemical (IHC)
staining for PlGF was performed on biopsies of aGVHD target
organs.
Results: PlGF levels and VEGFR1 expression: PlGF levels
were 3.5-fold higher (25.1 versus 7.1 pg/mL, p¼0.006) in
recipients at 3 months post-HCT compared to their MSD and
negatively associated with steroid dose (r¼-0.6, p¼0.02).
Allogeneic HCT recipients had signiﬁcantly higher levels of
circulating monocytes (15.4 vs 8.1%, p¼0.05) and approxi-
mately double the percentage of both CD8+ T-cell (1.5 vs 0.6%,
p¼0.009) and CD3-CD11b+DR(lo) myeloid-derived suppres-
sor cell (6.0 vs 3.3%, p¼0.01) subsets expressing VEGFR1,
compared to MSDs. PlGF tissue expression: Seven of 9 skin
biopsies were consistent with aGVHD by pathology review.
PlGF was present at 2-3+ staining intensity in all 7 cases of
skin aGVHD, while the 2 cases without aGVHD, as well as
normal skin, had little to no PlGF staining (0-1+). In contrast,
control GI tissues showed higher PlGF staining (2-3+). Four-
teen of 15 GI biopsies were consistent with aGVHD. PlGF
expression in patients with GI aGVHD was less intense than
control GI biopsies in 11/15 cases, with lowest scores
observed in two patients who died of steroid refractory GI
aGVHD.
Conclusion: Elevated PlGF in HCT recipients is associated
with an increase in monocytes and VEGFR1-expressing
